41st Annual J.P. Morgan Healthcare Conference
We are the innovation leader in bioprocessing
Enabling efficient, single-use, high productivity biological drug manufacturing
History of exceptional growth and expansion:
$800M
2022e
Revenue
+19%-20%
vs. 2021
Differentiated
technologies
R REPLIGEN
+41%
5-year CAGR
+26%
5-year avg.
base revenue
growth
Innovation,
acquisitions,
market strength
~30%
2022e Revenue
from new markets
(COVID & GT)
~70%
mAbs/other
Diversified customer
base, all biological drug
modalities
10
Disruptive
technology
launches
~26% of our revenue in
2022
65%
Clinical
35%
Commercial
(excl. COVID)
300
person
commercial
team
Late-stage clinical
pipeline will drive
growth
2022e figures reflects guidance as of our Q3 earnings call Nov. 1, 2022. "Base" excludes COVID-related & inorganic M&A revenue, includes FX impact.
4View entire presentation